Co-primary endpoints were met , with demonstration of superiority for each secukinumab dose vs. placebo at week 12 ( PASI 75 : 759 % , 695 % and 0 % for secukinumab 300mg , 150mg and placebo ; IGA mod 2011 0/1 : 690 % , 525 % and 0 % , respectively ; P < 00001 for all comparisons vs. placebo ) .